Brief: Transcenta Says Received IND Clearance From FDA For Its First-In-Class Gremlin1 Targeting Antibody TST003 For The Treatment Of Solid Tumors
14/09/2022 07:17
Sept 14 (Reuters) - Transcenta Holding Limited 6628.HK :
* TRANSCENTA RECEIVED IND CLEARANCE FROM FDA FOR ITS
FIRST-IN-CLASS GREMLIN1 TARGETING ANTIBODY TST003 FOR THE
TREATMENT OF SOLID TUMORS
Source text for Eikon: ID:nPn99GyRsa
Further company coverage: 6628.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcenta Holding
See all newsBrief: Transcenta Says Global Phase III Trial Of Osemitamab Approved By FDA, China, Korea Regulators
Brief: Transcenta Holding Says Unit To Sell CDMO Assets For RMB190.0 Million
Brief: Transcenta Holding To Revert Assets To Lilly For $4 Million Cash
Brief: Transcenta Therapeutics Appoints Dr. Christopher Hwang As Head Of Global Partnerships For Hicb Platform
Brief: Transcenta Announces Collaboration And Non-Exclusive Licensing Agreement With Eirgenix Inc.